Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 64
Filter
1.
Integr Biol (Camb) ; 11(3): 99-108, 2019 Mar 01.
Article in English | MEDLINE | ID: mdl-31083709

ABSTRACT

Label-free, holistic assays, monitoring, for example, the impedance of cells on electrodes, are gaining increasing popularity in the evaluation of G-protein-coupled receptor (GPCR) ligands. It is the strength of these approaches to provide the integrated cellular response non-invasively, highly automated and with a device-dependent time resolution down to several milliseconds. With an increasing number of samples to be studied in parallel, the available time resolution is, however, reduced and the cost for the disposable sensor arrays may become limiting. Inspired by protocols from organ pharmacology, we investigated a simple serial agonist addition assay that circumvents these limitations in impedance-based cellular assays. Using a serial addition of increasing concentrations of a GPCR agonist while continuously monitoring the sample's impedance, we were able to establish a full concentration-response curve for the endogenous agonist histamine on a single layer of U-373 MG cells endogenously expressing the histamine 1 receptor (H1R). This approach is validated with respect to conventional, parallel agonist addition protocols and studies using H1R antagonists such as mepyramine. Applicability of the serial agonist addition assay was shown for other GPCRs known for their signaling via one of the canonical G-protein pathways, Gq, Gi/0 or Gs as well. The serial agonist addition protocol has the potential to further strengthen the output of label-free analysis of GPCR activation.

2.
Pharmacol Res ; 114: 13-26, 2016 12.
Article in English | MEDLINE | ID: mdl-27751876

ABSTRACT

A set of histamine H1 receptor (H1R) agonists and antagonists was characterized in functional assays, using dynamic mass redistribution (DMR), electric cell-substrate impedance sensing (ECIS) and various signaling pathway specific readouts (Fura-2 and aequorin calcium assays, arrestin recruitment (luciferase fragment complementation) assay, luciferase gene reporter assay). Data were gained from genetically engineered HEK293T cells and compared with reference data from GTPase assays and radioligand binding. Histamine and the other H1R agonists gave different assay-related pEC50 values, however, the order of potency was maintained. In the luciferase fragment complementation assay, the H1R preferred ß-arrestin2 over ß-arrestin1. The calcium and the impedimetric assay depended on Gq coupling of the H1R, as demonstrated by complete inhibition of the histamine-induced signals in the presence of the Gq inhibitor FR900359 (UBO-QIC). Whereas partial inhibition by FR900359 was observed in DMR and the gene reporter assay, pertussis toxin substantially decreased the response in DMR, but increased the luciferase signal, reflecting the contribution of both, Gq and Gi, to signaling in these assays. For antagonists, the results from DMR were essentially compatible with those from conventional readouts, whereas the impedance-based data revealed a trend towards higher pKb values. ECIS and calcium assays apparently only reflect Gq signaling, whereas DMR and gene reporter assays appear to integrate both, Gq and Gi mediated signaling. The results confirm the value of the label-free methods, DMR and ECIS, for the characterization of H1R ligands. Both noninvasive techniques are complementary to each other, but cannot fully replace reductionist signaling pathway focused assays.


Subject(s)
Histamine Agonists/pharmacology , Histamine H1 Antagonists/pharmacology , Receptors, Histamine H1/metabolism , Calcium/metabolism , Drug Evaluation, Preclinical , Electric Impedance , GTP-Binding Proteins/metabolism , Genes, Reporter , HEK293 Cells , Histamine/pharmacology , Humans , Ligands , Radioligand Assay , Signal Transduction/drug effects , beta-Arrestins/metabolism
3.
Pharmacol Res ; 108: 65-74, 2016 06.
Article in English | MEDLINE | ID: mdl-27133553

ABSTRACT

Label-free cell-based assays have been attracting growing attention in drug research. Optical approaches based on evanescent electric fields (e.g. EPIC, RWG/DMR, SPR) and electrochemical impedance analysis (ECIS, xCELLigence) are by far the most widespread techniques for such purposes. We compared three label-free approaches (ECIS, RWG/DMR and SPR) with respect to the activation of the human histamine H1 receptor (H1R) expressed by U-373 MG glioblastoma and genetically engineered HEK 293T cells. HEK 293T cells were either expressing the hH1R alone or in combination with the adhesion protein hMSR1. The ß2-adrenergic receptor (ß2-AR) expressed by bovine aortic endothelial cells (BAEC) served as a second cell model. Reduced cell adhesion to the surface of the sensing devices affected both, the optical and the impedance-based readout, but became much more obvious in case of RWG- or SPR-based assays. By contrast, the co-expression of hH1R and hMSR1 in HEK 293T cells strongly enhanced the signal compared to hH1R expression alone. As the sensitivity of the optical readouts is confined to a distance of 100-200nm from the surface, depending on the wavelength of the incident light, this observation is in accordance with tighter adhesion of the co-transfectants, inducing a shorter distance between the cell membrane and the substrate. Combining ECIS and SPR, allowing for simultaneous registration of both signals for a single cell population, provided a direct correlation of both readouts, when H1R or ß2-AR stimulation was investigated for the same cell populations. Cell adhesion was found to have a critical impact on the results of label-free cell monitoring, in particular when techniques based on evanescent electric fields are applied.


Subject(s)
Cell Adhesion , Receptors, G-Protein-Coupled/metabolism , Animals , Cattle , Cell Line, Tumor , Electrochemical Techniques/instrumentation , Equipment Design , HEK293 Cells , Humans , Light , Refractometry , Signal Transduction , Surface Plasmon Resonance/instrumentation
4.
J Pharm Biomed Anal ; 104: 137-43, 2015 Feb.
Article in English | MEDLINE | ID: mdl-25499654

ABSTRACT

Esters of the cytostatic bendamustine (1), previously demonstrated to be much more potent than the parent compound as antiproliferative agents in vitro, were investigated for stability in buffer and plasma, as well as against porcine liver esterase in the presence of different amounts of albumin using a validated RP-HPLC method with fluorescence detection. The hydrolysis of the nitrogen mustard moiety was retarded (for 1: approximately 130 vs. 11 min) in the presence of plasma proteins. For the derivatives, both cleavage of ester and nitrogen mustard moieties were analyzed. Enzymatic hydrolysis was very fast in the case of 2-pyrrolidino-, 2-piperidino- and 2-(4-methylpiperazino)-ethyl esters, whereas methyl, ethyl, morpholinoethyl and branched 2-pyrrolidinoethyl esters were considerably more stable (half-lives between 41 and 116 min, compared to <5 min). Inhibition by physostigmine indicated unspecific cholinesterases to be involved in the rapid ester cleavage. Due to lower protein content and higher enzymatic activity in murine compared to human plasma, reduced stability of all investigated esters in mouse plasma (t½<2 min) has to be taken into account with respect to the design of animal studies.


Subject(s)
Nitrogen Mustard Compounds/blood , Animals , Bendamustine Hydrochloride , Chromatography, High Pressure Liquid/methods , Esters/blood , Humans , Mice , Mice, Nude , Pharmacokinetics
5.
Br J Pharmacol ; 172(3): 785-98, 2015 Feb.
Article in English | MEDLINE | ID: mdl-24903527

ABSTRACT

BACKGROUND AND PURPOSE: Some histamine H4 receptor ligands act as inverse agonists at the human H4 receptor (hH4 R), a receptor with exceptionally high constitutive activity, but as neutral antagonists or partial agonists at the constitutively inactive mouse H4 receptor (mH4 R) and rat H4 receptor (rH4 R). To study molecular determinants of constitutive activity, H4 receptor reciprocal mutants were constructed: single mutants: hH4 R-F169V, mH4 R-V171F, hH4 R-S179A, hH4 R-S179M; double mutants: hH4 R-F169V+S179A, hH4 R-F169V+S179M and mH4 R-V171F+M181S. EXPERIMENTAL APPROACH: Site-directed mutagenesis with pVL1392 plasmids containing hH4 or mH4 receptors were performed. Wild-type or mutant receptors were co-expressed with Gαi2 and Gß1 γ2 in Sf9 cells. Membranes were studied in saturation and competition binding assays ([(3) H]-histamine), and in functional [(35) S]-GTPγS assays with inverse, partial and full agonists of the hH4 receptor. KEY RESULTS: Constitutive activity decreased from the hH4 receptor via the hH4 R-F169V mutant to the hH4 R-F169V+S179A and hH4 R-F169V+S179M double mutants. F169 alone or in concert with S179 plays a major role in stabilizing a ligand-free active state of the hH4 receptor. Partial inverse hH4 receptor agonists like JNJ7777120 behaved as neutral antagonists or partial agonists at species orthologues with lower or no constitutive activity. Some partial and full hH4 receptor agonists showed decreased maximal effects and potencies at hH4 R-F169V and double mutants. However, the mutation of S179 in the hH4 receptor to M as in mH4 receptor or A as in rH4 receptor did not significantly reduce constitutive activity. CONCLUSIONS AND IMPLICATIONS: F169 and S179 are key amino acids for the high constitutive activity of hH4 receptors and may also be of relevance for other constitutively active GPCRs. LINKED ARTICLES: This article is part of a themed issue on Histamine Pharmacology Update published in volume 170 issue 1. To view the other articles in this issue visit http://onlinelibrary.wiley.com/doi/10.1111/bph.2013.170.issue-1/issuetoc.


Subject(s)
Receptors, G-Protein-Coupled/genetics , Receptors, G-Protein-Coupled/metabolism , Receptors, Histamine/genetics , Receptors, Histamine/metabolism , Humans , Indoles/pharmacology , Ligands , Models, Molecular , Molecular Structure , Mutagenesis, Site-Directed , Piperazines/pharmacology , Receptors, G-Protein-Coupled/antagonists & inhibitors , Receptors, Histamine H4 , Structure-Activity Relationship
6.
J Nanosci Nanotechnol ; 14(5): 3313-9, 2014 May.
Article in English | MEDLINE | ID: mdl-24734546

ABSTRACT

The biodistribution of nanoparticles is a major subject of current nanomedical research. To date, however, the exact investigation of nanoparticle fate in the microenvironment of a main excretory organ, the kidney has largely been neglected. In this study, the biodistribution of polyethylene glycol-coated quantum dots (Qdots) with special focus on their interaction with the kidney is investigated. Upon intravenous injection, nanoparticles showed effective blood circulation in mice and significant renal accumulation after two hours. Histological analysis of the kidney revealed that Qdots were strongly associated to the intraglomerular mesangial cells. This preferential deposition of nanoparticles in the kidney mesangium is highly promising, since it could be of utmost value for site-specific treatment of severe kidney diseases like diabetic nephropathy in the future.


Subject(s)
Kidney/metabolism , Quantum Dots , Animals , Injections, Intravenous , Male , Mice , Mice, Nude , Microscopy, Confocal , Microscopy, Electron, Transmission , Polyethylene Glycols/pharmacokinetics , Spectrometry, Fluorescence , Tissue Distribution
7.
Regul Pept ; 107(1-3): 49-62, 2002 Jul 15.
Article in English | MEDLINE | ID: mdl-12137966

ABSTRACT

In Chinese hamster ovary (CHO) cells expressing the cloned guinea-pig Y1 receptor, the saturable, receptor-linked internalization of NPY (NPY)-related peptides showed the rank order of human/rat neuropeptide Y (hNPY)>pig/rat peptide YY (pPYY)>=(Pro(34))human PYY>(Leu(31),Pro(34))hNPY>(Leu(31),Pro(34))hPYY>>BVD-11 (a selective Y1 antagonist). All agonists accessed similar numbers of Y1 sites in particulates from disrupted cells, with relatively small affinity variation. The rate of internalization could significantly depend on the overall interactivity of the agonist peptide (reflected in sensitivity to chaotropic agents, as well as in the level of non-saturable binding and internalization). Concentration-dependent inhibition of the agonist-driven CHO-Y1 internalization was found with filipin III (a cholesterol-complexing macrolide), and confirmed with inhibitors of clathrin lattice formation, phenylarsine oxide (PAO) and sucrose. In the concentration range affecting Y1 internalization, none of the above treatments or agents significantly alter agonist affinity for Y1 cell surface or particulate receptors. Largely similar responses to the above inhibitors were observed in CHO-Y1 cells for internalization of human transferrin. Internalization of CHO-Y1 receptor apparently is driven by NPY in strong preference to other naturally encountered agonists. At 37 degrees C, most of the internalized receptor is rapidly recycled through endosome-like membrane elements, detectable in Percoll gradients.


Subject(s)
Endosomes/drug effects , Receptors, Neuropeptide Y/agonists , Animals , Arsenicals/pharmacology , Binding Sites , Binding, Competitive , CHO Cells , Cloning, Molecular , Cricetinae , Cricetulus , Filipin/pharmacology , Guinea Pigs , Iodine Radioisotopes , Kinetics , Neuropeptide Y/metabolism , Receptors, Neuropeptide Y/genetics , Receptors, Neuropeptide Y/metabolism , Sucrose/pharmacology , Temperature
8.
Int J Pharm ; 238(1-2): 111-21, 2002 May 15.
Article in English | MEDLINE | ID: mdl-11996815

ABSTRACT

Nude mice were challenged with human U-87 MG glioblastoma tumors to assess the efficacy of different cytostatics and different application protocols. While the intraperitoneal application of BCNU solutions (3 times 20 mg BCNU/kg) had no effect on tumor growth, the application of polymer matrices made of a physical mixture of poly(1,3-bis[carboxyphenoxpropane]-co-sebacic acid) 20:80 with poly(D,L-lactic-co-glycolic acid) loaded with 0.25 mg BCNU, slowed down the growth of tumors significantly. When the animals were treated with implants carrying 0.25 mg BCNU they responded to the treatment whether the tumor had been inoculated recently (9 days ago) or whether it was fully established (after 20 days). After its sensitivity was proven, the xenograft model was used to further investigate the efficacy of anticancer drugs and some treatment regimens using polymer implants. Thus the tumor model allowed to discriminate between the efficacy of different doses of BCNU. Only implants loaded with 0.75 or 1 mg of BCNU led to a substantial suppression of tumor growth over approximately 2 months. While BCNU was only able to suppress the growth of the tumor, the combination of BCNU with paclitaxel led to a complete remission in some animals. These preliminary results suggest that combinations of cytostatics might improve local chemotherapy of malignant glioma substantially. Based on our data it will be worthwhile to investigate implants that release drugs such as BCNU and paclitaxel closer. Amongst other factors we will try to elucidate the effect of repetitive doses of drugs using programmable implants.


Subject(s)
Antineoplastic Agents, Alkylating/administration & dosage , Antineoplastic Agents, Alkylating/pharmacology , Antineoplastic Agents, Phytogenic/administration & dosage , Antineoplastic Agents, Phytogenic/therapeutic use , Brain Neoplasms/drug therapy , Carmustine/administration & dosage , Carmustine/therapeutic use , Glioblastoma/drug therapy , Paclitaxel/administration & dosage , Paclitaxel/therapeutic use , Animals , Brain Neoplasms/pathology , Dose-Response Relationship, Drug , Drug Implants , Excipients , Glioblastoma/pathology , Humans , Mice , Mice, Nude , Neoplasm Transplantation , Polymers
9.
J Pharmacol Exp Ther ; 299(3): 1013-20, 2001 Dec.
Article in English | MEDLINE | ID: mdl-11714890

ABSTRACT

Fusion proteins allow for the analysis of receptor/G protein coupling under defined conditions. The beta(2)-adrenoceptor (beta(2)AR) fused to the long splice variant of G(salpha) (G(salphaL)) exhibits a higher apparent constitutive activity than the beta(2)-adrenoceptor fused to the short splice variant of G(salpha) (G(salphaS)). Experimentally, this results in higher efficacy and potency of partial agonists and in higher efficacy of inverse agonists at the beta(2)AR fused to G(salphaL) relative to the beta(2)AR fused to G(salphaS), indicating that the agonist-free beta(2)AR and the beta(2)AR occupied by partial agonists promote GDP dissociation from G(salphaL) more efficiently than from G(salphaS). In fact, the GDP affinity of G(salphaS) fused to the beta(2)AR is higher than the GDP affinity of G(salphaL) fused to the beta(2)AR. We asked the question whether the histamine H(2)-receptor (H(2)R) exhibits similar coupling to G(salpha) splice variants as the beta(2)AR. To address this question, we studied H(2)R-G(salpha) fusion proteins expressed in Sf9 cells. In contrast to beta(2)AR-G(salpha) fusion proteins, the potencies and efficacies of partial agonists and the efficacies of inverse agonists were similar at the H(2)R fused to G(salphaL) and G(salphaS) as assessed by guanosine-5'-O-(3-thio)triphosphate binding and/or steady-state GTPase activity. However, the time course analysis of guanosine-5'-O-(3-thio)triphosphate binding indicated that G(salphaS) fused to the H(2)R possesses a higher GDP-affinity than G(salphaL) fused to the H(2)R. Our data show that the H(2)R fused to G(salphaL) and G(salphaS) possesses similar constitutive activity and is insensitive to differences in GDP affinity of G(salpha) splice variants. Thus, GDP affinity of G proteins does not generally determine constitutive activity of receptors.


Subject(s)
Cimetidine/analogs & derivatives , GTP-Binding Protein alpha Subunits, Gs/metabolism , Receptors, Histamine H2/metabolism , Alternative Splicing , Animals , Cell Membrane/metabolism , Cells, Cultured , Cimetidine/pharmacology , GTP Phosphohydrolases/drug effects , GTP Phosphohydrolases/metabolism , GTP-Binding Protein alpha Subunits, Gs/genetics , Guanidine/analogs & derivatives , Guanidine/pharmacology , Guanosine 5'-O-(3-Thiotriphosphate)/metabolism , Histamine Agonists/pharmacology , Histamine H2 Antagonists/pharmacology , Humans , Insecta , Radioligand Assay , Receptors, Histamine H2/genetics , Recombinant Fusion Proteins/metabolism , Sulfur Radioisotopes , Transfection , Tritium
10.
Mol Pharmacol ; 60(6): 1210-25, 2001 Dec.
Article in English | MEDLINE | ID: mdl-11723228

ABSTRACT

It is unknown why the potencies and efficacies of long-chained guanidine-type histamine H2-receptor (H2R) agonists are lower at the H2R of human neutrophils than at the H2R of the guinea pig atrium. To elucidate these differences, we analyzed fusion proteins of the human H2R (hH2R) and guinea pig H2R (gpH2R), respectively, and the short splice variant of Gsalpha (GsalphaS) expressed in Sf9 cells. The potencies and efficacies of small H2R agonists in the GTPase assay and the potencies of antagonists at inhibiting histamine-stimulated GTP hydrolysis by hH2R-GsalphaS and gpH2R-GsalphaS were similar. In contrast, the potencies and efficacies of guanidines were lower at hH2R-GsalphaS than at gpH2R-G(salphaS). Guanidines bound to hH2R-GsalphaS with lower affinity than to gpH2R-GsalphaS, and high-affinity binding of guanidines at gpH2R-GsalphaS was more resistant to disruption by GTPgammaS than binding at hH2R-GsalphaS. Molecular modeling suggested that the nonconserved Asp-271 in transmembrane domain 7 of gpH2R (Ala-271 in hH2R) confers high potency to guanidines. This hypothesis was confirmed by Ala-271-->Asp-271 mutation in hH2R-GsalphaS. Intriguingly, the efficacies of guanidines at the Ala-271-->Asp-271 mutant and at hH2R/gpH2R chimeras were lower than at gpH2R. Our model suggests that a Tyr-17/Asp-271 H-bond, present only in gpH2R-GsalphaS but not the other constructs studied, stabilizes the active guanidine-H2R state. Collectively, our data show 1) distinct interaction of H2R species isoforms with guanidines, 2) that a single amino acid in transmembrane domain 7 critically determines guanidine potency, and 3) that an interaction between transmembrane domains 1 and 7 is important for guanidine efficacy.


Subject(s)
Cimetidine/analogs & derivatives , Guanidine/pharmacology , Histamine Agonists/pharmacology , Receptors, Histamine H2/metabolism , Alternative Splicing , Amino Acid Sequence , Animals , Binding Sites , Cell Membrane/metabolism , Cells, Cultured , Cimetidine/metabolism , GTP-Binding Protein alpha Subunits, Gs/genetics , GTP-Binding Protein alpha Subunits, Gs/metabolism , Guanidine/analogs & derivatives , Guanidine/chemistry , Guanidines/pharmacology , Guanosine 5'-O-(3-Thiotriphosphate)/metabolism , Guinea Pigs , Humans , Insecta , Models, Molecular , Molecular Sequence Data , Piperidines/pharmacology , Protein Conformation/drug effects , Protein Isoforms , Ranitidine/pharmacology , Receptors, Histamine H2/drug effects , Receptors, Histamine H2/genetics , Sequence Homology, Amino Acid , Species Specificity , Structure-Activity Relationship , Sulfur Radioisotopes , Tritium
11.
J Control Release ; 73(1): 75-88, 2001 May 18.
Article in English | MEDLINE | ID: mdl-11337061

ABSTRACT

Pulsatile release implants were developed that release substances up to 58 days post implantation. With a cylindrical size of 2 mm diameter and 1.8 mm height the matrices can carry as much as 1 mg of drug and allow even for intracranial implantation into a rodent model. The matrices are made of materials that have been used for parenteral applications in humans before such as surface eroding polyanhydrides and bulk eroding poly(D,L-lactic acid) or poly(D,L-lactic acid-co-glycolic acid). The onset of drug release is controlled by the degradation of bulk eroding polymers which are known to exhibit a certain stability over a defined period of time and which start eroding after they reach a critical degree of degradation. The time of drug release onset was found to depend on the molecular weight and the chemical state of the carboxylic acid end of the polymer chain. For testing the onset of release in vivo a nude mouse model was developed where the release of Evan's blue could be observed visually after subcutaneous application. By combining individual matrices with different release onset, a therapeutic system can be composed that releases drugs after implantation at predetermined time points in a preprogrammed way. Potential applications for such matrices is vaccination and local tumor therapy.


Subject(s)
Absorbable Implants , Anhydrides/chemical synthesis , Anhydrides/chemistry , Animals , Calorimetry, Differential Scanning , Coloring Agents , Drug Carriers , Evans Blue , Indicators and Reagents , Injections, Subcutaneous , Kinetics , Lactic Acid , Mice , Mice, Nude , Microscopy, Electron, Scanning , Polyglycolic Acid , Polylactic Acid-Polyglycolic Acid Copolymer , Polymers
12.
Chirality ; 13(6): 285-93, 2001 Jun.
Article in English | MEDLINE | ID: mdl-11370017

ABSTRACT

Analytical CE and HPLC methods were developed for the chiral separation of halogen-substituted 3-phenyl-3-(2-pyridyl)propylamines 1-4 (1: 3-(4-fluorophenyl) approximately, 2: 3-(3,4-difluorophenyl) approximately, 3: 3-(4-chlorophenyl) approximately, 4: 3-(3,4-dichlorophenyl) approximately ), 3-(4-fluorophenyl)-3-(2-thiazolyl)propylamine (5), and 3-(4-fluorophenyl)-3-(1-benzylimidazol-2-yl)propylamine (6), which are building blocks for the preparation of very potent arpromidine-type histamine H(2) receptor agonists. All amines were enantioseparated by CE with resolutions of at least 1.8 using alpha-, beta-, or gamma-cyclodextrin (CD) as chiral selectors. With heparin as buffer additive for CE the optical antipodes of 1-4 and 6 were separated with resolutions > or = 1.8. On RP-18 columns the separation of the (+)-(S)-acetylmandelic acid amides of racemic 2 (R = 0.9, alpha = 1.07) and the thioureas prepared by addition of 6 to 2,3,4,6-tetra-O-acetyl-beta-D-glucopyranosyl isothiocyanate (R = 2.0, alpha = 1.20) was successful, whereas the diastereomeric ureas prepared from 3 and (+)-(S)-1-(1-naphthyl)ethyl isocyanate could not be resolved. Separation of the diastereomeric isoindoles prepared from 1-5, o-phthaldialdehyde and 2,3,4,6-tetra-O-acetyl-1-thio-beta-D-glucopyranoside was achieved on a RP-18 phase (R > or = 0.4, a > or = 1.02). Direct separation of the enantiomers of 3 and 4 was achieved on a Cyclobond I column (R > or = 0.9, alpha > or = 1.07). alpha- and beta-CD were also useful as mobile phase additives for HPLC (3 and 4: RP-18 column, beta-CD, R > or = 0.4, alpha > or = 1.03; 3: RP-18 column, alpha-CD: R = 0.5, alpha = 1.04).


Subject(s)
Chromatography, High Pressure Liquid/methods , Electrophoresis, Capillary/methods , Pheniramine/chemistry , Propylamines/isolation & purification , Cyclodextrins/chemistry , Heparin/chemistry , Propylamines/chemistry , Stereoisomerism
13.
Peptides ; 22(3): 387-94, 2001 Mar.
Article in English | MEDLINE | ID: mdl-11287093

ABSTRACT

In HEC-1B cells transfected with human Y(5) neuropeptide Y (NPY) receptors (but not in non-transfected cells) NPY inhibited forskolin-stimulated cAMP accumulation in a pertussis toxin-sensitive manner (-log EC(50) 8.88 +/- 0.25). Elevations of intracellular Ca(2+) were largely restricted to very high NPY concentrations and similar in transfected and nontransfected cells. NPY did not increase inositol phosphate accumulation and did not activate a variety of isoforms of protein kinase C or mitogen-activated protein kinases. We conclude that at least upon expression in HEC-1B cells the signal transduction of Y(5) NPY receptors is limited to inhibition of cAMP accumulation.


Subject(s)
Receptors, Neuropeptide Y/chemistry , Receptors, Neuropeptide Y/metabolism , Signal Transduction , Analysis of Variance , Animals , CHO Cells , COS Cells , Calcium/metabolism , Cell Line , Colforsin/metabolism , Cricetinae , Cyclic AMP/metabolism , Dose-Response Relationship, Drug , Enzyme Activation , Humans , Inositol Phosphates/metabolism , MAP Kinase Signaling System , Pertussis Toxin , Phosphates/metabolism , Protein Isoforms , Protein Kinase C/chemistry , Protein Kinase C/metabolism , Time Factors , Transfection , Virulence Factors, Bordetella/metabolism
14.
Bioorg Med Chem Lett ; 10(14): 1597-600, 2000 Jul 17.
Article in English | MEDLINE | ID: mdl-10915060

ABSTRACT

Analogues of BIBP 3226, (R)-N(alpha)-diphenylacetyl-N-(4-hydroxybenzyl)argininamide, were synthesized and investigated for Y1 antagonism (Ca2+-assay, HEL cells) and binding on Y1, Y2 and Y5 receptors. Replacing the benzylamino by a tetrahydrobenzazepinyl group preserves most of the Y1 activity. Combination with a N(G)-phenylpropyl arginine and a N(alpha)-p-biphenylylacetyl moiety shifted the NPY receptor selectivity towards Y5.


Subject(s)
Arginine/analogs & derivatives , Arginine/chemistry , Receptors, Neuropeptide Y/antagonists & inhibitors , Animals , Arginine/chemical synthesis , Arginine/pharmacology , Drug Design , Humans , Kinetics , Leukemia, Erythroblastic, Acute , Molecular Conformation , Molecular Structure , Neuropeptide Y/pharmacokinetics , Structure-Activity Relationship , Swine , Tumor Cells, Cultured
16.
Can J Physiol Pharmacol ; 78(2): 108-15, 2000 Feb.
Article in English | MEDLINE | ID: mdl-10737673

ABSTRACT

The design of non-peptide, Y1-selective antagonists of neuropeptide Y (NPY) as pharmacological tools is in progress and is increasingly important as therapeutic applications are expected. Starting from the potent histamine H2 agonist and weak NPY Y1 antagonist arpromidine, 16 imidazolylpropylguanidine derivatives were synthesized and tested for Y1 antagonistic activity (inhibition of NPY-stimulated Ca2+ increase in human erythroleukemic cells), where the pheniramine-like moiety of arpromidine was replaced with 2-pyridylaminoalkyl, benzyl-(2-pyridyl)aminoalkyl, and phenyl-(2-pyridyl)alkylaminoalkyl partial structures derived from mepyramine. The pA2 values of the most active compounds are in the range of 6.2-6.5. Quantitative structure-activity relationships (QSAR) were investigated by fragment regression analysis. Results indicate that a tetramethylene spacer between the guanidino group and the amino nitrogen is optimal. For an at least moderate degree of Y1 antagonistic activity, a second benzyl or phenyl group must be present in addition to the 2-pyridyl ring. At this second group, hydrophobic substituents such as 3,4-di-CI and 4-Br further enhance Y1 antagonism. The most active derivative additionally bears a 5-Br substituent at the 2-pyridyl moiety. Structure-activity relationships suggest that the compounds might be able to partially imitate the role of NPY when interacting with Y1 receptors and thus behave as moderate non-peptide NPY Y1 antagonists.


Subject(s)
Guanidines/pharmacology , Receptors, Neuropeptide Y/antagonists & inhibitors , Humans , Structure-Activity Relationship
17.
Can J Physiol Pharmacol ; 78(2): 134-42, 2000 Feb.
Article in English | MEDLINE | ID: mdl-10737676

ABSTRACT

Aiming to develop a functional assay for the human NPY Y5 receptor based on adenylyl cyclase activity, HEC-1B cells, in which cAMP synthesis can be efficiently stimulated with forskolin, were selected for the transfection with the pcDNA3-Y5-FLAG and the pcDEF3-Y5 vectors. After optimization of the transfection procedure, the binding of [3H]propionyl-NPY to transiently and stably expressed Y5 receptors was determined. The affinities of NPY, NPY derivatives, and rPP (pNPY > or = p(Leu31Pro34)NPY = p(2-36)NPY > or = p(D-Trp32)NPY > p(13-36)NPY > rPP) were in accordance with the NPY Y5 receptor subtype. For [3H]propionyl-pNPY approximately 1.7 x 10(5) and 1 x 10(6) binding sites per transiently and stably transfected cell, respectively, were determined. The KD values were 2.4 +/- 0.4 and 1.7 +/-0.2 nM, respectively. Due to the high expression of the receptor protein, both stably and transiently transfected cells can be conveniently used in routine radioligand binding studies. By contrast, functional assays were only feasible with HEC-1B cells stably expressing the Y5 receptor. In these cells, 10 nM pNPY inhibited the forskolin-stimulated cAMP synthesis by 75%. This effect was partially antagonized by the Y5 antagonist N-¿trans-[4-(2-naphthylmethylamino)-methyl]cyclohexylmethyl) naphthalene-2-sulfonamide. Although the genetic variability of cancer cells is in principle incompatible with a stable phenotype, both ligand binding characteristics and functionality of the Y5 receptor remained unchanged for more than 30 passages.


Subject(s)
Endometrial Neoplasms/chemistry , Receptors, Neuropeptide Y/genetics , Cloning, Molecular , Cyclic AMP/biosynthesis , Female , Humans , Polymerase Chain Reaction , Radioligand Assay , Receptors, Neuropeptide Y/physiology , Transfection , Tumor Cells, Cultured
18.
Planta Med ; 65(6): 512-6, 1999 Aug.
Article in English | MEDLINE | ID: mdl-10483369

ABSTRACT

The effect of an extract of Thymus vulgaris on induced spasms was investigated on guinea-pig trachea preparations. By the experimental setup used, effects of ethanol as the vehicle could be differentiated from the activity of the herbal constituents. The extract reversibly and concentration-dependently antagonized the contraction of the Musculus transversus tracheae, provoked by four different spasmogens (BaCl2, carbachol, histamine, prostaglandin F2 alpha). The degree of the antispasmodic activity was dependent on the individual spasmogen with prostaglandin F2 alpha being most efficiently antagonized.


Subject(s)
Lamiaceae , Muscle Contraction/drug effects , Muscle, Smooth/drug effects , Parasympatholytics/pharmacology , Plant Extracts/pharmacology , Trachea/drug effects , Animals , Ethanol/pharmacology , Guinea Pigs , In Vitro Techniques , Muscle, Smooth/physiology , Trachea/physiology
19.
Cancer Lett ; 131(1): 13-20, 1998 Sep 11.
Article in English | MEDLINE | ID: mdl-9839615

ABSTRACT

The Morgan-Elson reaction, a method for the determination of hyaluronidase activity, was optimized for the quantitation of the enzyme in biological material. Based on HPLC and spectrometric (UV-Vis, LC-MS) studies, the structure of the red-colored product (mesomeric forms of N3-protonated 3-acetylimino-2-(4-dimethylaminophenyl)methylidene-5-(1,2-++ +dihydroxyethyl)furane) formed by condensation of chromogen III with p-dimethylaminobenzaldehyde is proposed. Activities corresponding to > or = 0.1 IU of endogenous and therapeutically administered hyaluronidase can be detected in 50 microl samples. Application of the method for the determination of the enzyme in plasma of tumor patients revealed no difference in activity levels, interindividual variability and pH profile compared to healthy volunteers.


Subject(s)
Hyaluronoglucosaminidase/blood , Neoplasms/enzymology , Adult , Aged , Carbohydrate Sequence , Case-Control Studies , Colorimetry , Humans , Hydrogen-Ion Concentration , Middle Aged , Molecular Sequence Data , Neoplasms/blood , Reference Values
20.
Cancer Lett ; 131(1): 71-84, 1998 Sep 11.
Article in English | MEDLINE | ID: mdl-9839622

ABSTRACT

The influence of the route of administration (i.v., i.p. and s.c.) on pharmacokinetics and tissue distribution of bovine testicular hyaluronidase and vinblastine was studied in mice (plasma, skeletal muscle, liver, kidney and human melanoma). After i.v. injection, hyaluronidase was accumulated in liver and kidney, whereas i.p. and s.c. administration led to almost equal distribution in plasma, muscle, liver and kidney. In melanoma, the highest levels of hyaluronidase were found after s.c. injection of the enzyme close to the tumor. Hyaluronidase s.c. increased the intratumoral concentration of s.c. co-administered vinblastine most efficiently, making local simultaneous application as in interstitial chemotherapy most promising.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Testis/enzymology , Animals , Antineoplastic Combined Chemotherapy Protocols/pharmacokinetics , Cattle , Chemotherapy, Adjuvant , Drug Administration Routes , Humans , Hyaluronoglucosaminidase/administration & dosage , Injections , Kidney/drug effects , Kidney/metabolism , Liver/drug effects , Liver/metabolism , Male , Melanoma/drug therapy , Melanoma/metabolism , Mice , Mice, Nude , Muscle, Skeletal/drug effects , Muscle, Skeletal/metabolism , Tissue Distribution , Vinblastine/administration & dosage
SELECTION OF CITATIONS
SEARCH DETAIL
...